• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·OSSD.ST
Share

OssDsign AB (publ) Stocks

SEK 4.12Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

SEK 45.43M

SEK 4.12
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

OssDsign AB (publ) specializes in the innovation, manufacturing, and distribution of advanced implant and material technologies crucial for bone regeneration. The company operates across a broad international market, including Sweden, Germany, the United States, the United Kingdom, the wider European region, and other global territories. Its product line features OSSDSIGN cranial, a comprehensive implant and accessory system engineered for the reconstruction of skull defects in cranioplasty procedures. Another key offering, OSSDSIGN facial, is designed to correct skeletal deformities, whether they arise from trauma or are congenital. Additionally, OssDsign provides the OSSDSIGN Cranioplug, which serves to secure bone flaps and cover burr holes, and OssDsign Catalyst, a cutting-edge nanosynthetic bone graft substitute specifically formulated to stimulate healthy bone tissue formation. Established in 2011, the company maintains its primary operational base in Uppsala, Sweden.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of OSSD.ST is 6.12 and suggests 53.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 22:21

Apple's market capitalization reached $5 trillion for the first time

28.07.2026 22:17

The EU is preparing a record-breaking package of sanctions against more than 1,600 Russian companies — media reports

28.07.2026 22:14

Boeing's loss was worse than expected. Why are its shares rising?

28.07.2026 21:58

U.S. senators have agreed on “severe sanctions” against Russia. What happens next?

28.07.2026 21:28

Apple Is Preparing for a Breakthrough in the Smart Home Market — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026